8-K: Philip Morris International Declares Quarterly Dividend of $1.35 Per Share

Philip Morris International announces a regular quarterly dividend of $1.35 per common share, payable on April 10, 2025, to shareholders of record as of March 20, 2025.

Summary

• Philip Morris International Inc. (PMI) has declared a regular quarterly dividend of $1.35 per common share.
• The dividend is payable on April 10, 2025, to shareholders of record as of March 20, 2025.
• The ex-dividend date is also March 20, 2025.
• PMI is focused on delivering a smoke-free future and expanding its portfolio beyond tobacco and nicotine products.
• The company has invested over $14 billion since 2008 in developing and commercializing smoke-free products.
• PMI's smoke-free products were available in 95 markets as of December 31, 2024.
• Approximately 38.6 million adults worldwide use PMI's smoke-free products.
• The smoke-free business accounted for approximately 39% of PMI's total full-year 2024 net revenues.
• PMI acquired Swedish Match in 2022, creating a global smoke-free champion.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the dividend announcement and the company's progress in smoke-free products, but tempered by the inherent risks associated with the tobacco industry.

Positives

• The declaration of a regular quarterly dividend provides a return to shareholders.
• PMI's focus on smoke-free products aligns with evolving consumer preferences and health concerns.
• The company's significant investment in smoke-free products demonstrates a commitment to innovation.
• The growing availability and adoption of smoke-free products indicate market acceptance.
• The increasing contribution of smoke-free products to net revenues suggests a successful transition.
• FDA authorization of IQOS and ZYN products validates PMI's scientific approach.

Risks

• The company faces regulatory risks associated with tobacco and nicotine products.
• Consumer preferences may shift away from smoke-free products.
• Competition in the smoke-free market is increasing.
• The company's expansion into wellness and healthcare areas may face challenges.

Future Outlook

PMI aims to deliver a smoke-free future and expand into wellness and healthcare areas.

Management Comments

• PMI is actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector.

Industry Context

The announcement reflects the ongoing shift in the tobacco industry towards smoke-free alternatives, driven by health concerns and changing consumer preferences. Competitors like British American Tobacco (BAT) and Altria are also investing heavily in smoke-free products.

Comparison to Industry Standards

• PMI's investment of over $14 billion in smoke-free products is significant compared to other tobacco companies.
• The 39% contribution of smoke-free products to PMI's revenue is a notable achievement, potentially exceeding some competitors' progress in this area.
• The FDA authorization of IQOS and ZYN products provides a competitive advantage for PMI.
• BAT, for example, is also focusing on smoke-free products with brands like Vuse and Glo, and Altria has invested in Juul (though with mixed results).

Stakeholder Impact

• Shareholders will receive a quarterly dividend of $1.35 per share.
• Employees are involved in the development and commercialization of smoke-free products.
• Customers have access to a growing range of smoke-free alternatives.
• Suppliers are involved in the production of both traditional tobacco products and smoke-free products.
• Creditors are exposed to the financial performance of PMI.

Key Dates